Alliance Wealth Advisors LLC UT Buys 542 Shares of Novo Nordisk A/S (NYSE:NVO)

Alliance Wealth Advisors LLC UT raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,395 shares of the company’s stock after purchasing an additional 542 shares during the period. Novo Nordisk A/S accounts for approximately 1.0% of Alliance Wealth Advisors LLC UT’s holdings, making the stock its 29th biggest position. Alliance Wealth Advisors LLC UT’s holdings in Novo Nordisk A/S were worth $2,834,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Capital Investment Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $222,000. Patriot Financial Group Insurance Agency LLC increased its position in shares of Novo Nordisk A/S by 14.2% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 5,522 shares of the company’s stock worth $502,000 after acquiring an additional 685 shares during the period. Ballentine Partners LLC boosted its stake in shares of Novo Nordisk A/S by 102.6% during the third quarter. Ballentine Partners LLC now owns 17,478 shares of the company’s stock valued at $1,589,000 after purchasing an additional 8,851 shares in the last quarter. Grimes & Company Inc. boosted its stake in shares of Novo Nordisk A/S by 88.6% during the third quarter. Grimes & Company Inc. now owns 100,881 shares of the company’s stock valued at $9,174,000 after purchasing an additional 47,395 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. boosted its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. Investment Research & Advisory Group Inc. now owns 432 shares of the company’s stock valued at $39,000 after purchasing an additional 216 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $1.06 on Friday, hitting $126.85. 3,312,457 shares of the company were exchanged, compared to its average volume of 3,307,405. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The stock’s 50 day moving average price is $126.86 and its 200 day moving average price is $111.98. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $569.24 billion, a P/E ratio of 46.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.